COMMITTED TO QUALITY
Type:
Administration Route :
Cancer Site:
Dosage form :
Tablets
Doses :
70/100 mg
Dotixa contains the active substance dasatinib. Dotixa is used to treat Philadelphia chromosome positive (pH+) Chronic Lymphoblastic Leukemia (CML) and Acute Lymphoblastic Leukemia (ALL) in adults, adolescents, and children at least 1 year of age who are not benefiting from prior therapies.
Dosage form :
Vials
Doses :
100/400 mg
Evacim contains the active substance bevacizumab, which is a humanised monoclonal antibody. Evacim binds selectively to a protein called human vascular endothelial growth factor (VEGF), which is found on the lining of blood and lymph vessels in the body. The VEGF protein causes blood vessels to grow within tumours, these blood vessels provide the tumour with nutrients and oxygen. Once bevacizumab is bound to VEGF, tumour growth is prevented by blocking the growth of the blood vessels which provide the nutrients and oxygen to the tumour.
Dosage form :
Capsules
Doses :
75/100/125 mg
Ibract is an anticancer medicine containing the active substance palbociclib. Palbociclib works by blocking proteins called cyclin-dependent kinase 4 and 6, which regulate cell growth and division. Blocking these proteins can slow down growth of cancer cells and delay the progression of cancer.
1
2
3
Next